Catalyst

Slingshot members are tracking this event:

In the first half of 2019., Esperion Therapeutics (ESPR) plans to submit a New Drug Application (NDA) for bempedoic acid aimed at lowering low density lipoprotein cholesterol (LDL-C)

Source Link:
https://seekingalpha.com/news/3252194-fda-board-esperions-late-stage-development-program-bad-cholesterol-lowering-claim-bempedoic

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ESPR Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 28, 2019
Occurred Source:
https://investor.esperion.com/news-releases/news-release-details/esperion-announces-submissions-two-ndas-and-official-completion
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Low Density Lipoprotein Cholesterol, Nda Filing, Bempedoic Acid
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.